Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials

• Main Authors: Bixi Gao (Author), Yanbo Yang (Author), Zilan Wang (Author), Yue Sun (Author), Zhouqing Chen (Author), Yun Zhu (Author), Zhong Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundAs one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide. Several clinical trials have been conducted to investigate the ef...